Durham-based AI drug developer Avicenna Biosciences has secured USD 6 million in debt financing according to a Securities and Exchange Commission (SEC) filing.
The funds will fuel the company’s ongoing drug discovery and development process to treat neurodegenerative diseases.
Founded in 2020, Avicenna Biosciences leverages machine learning-enhanced medicinal chemistry for drug development. This approach is designed to streamline the lead-to-candidate optimization process for small-molecule drug development. Currently, the company is focused on developing a treatment for Amyotrophic Lateral Sclerosis, a progressive neurodegenerative disease.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.